Northwest Biotherapeutics, Inc. (NWBO)

0.4600 -0.0059 (-1.27%) At close: 03:58PM EDT

Northwest Biotherapeutics, Inc.

4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
United States
240 497 9024
https://www.nwbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 25

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Linda F. Powers J.D.	Chairperson, CEO, President, CFO & Chief Accounting Officer	925k	N/A	1956
Dr. Alton L. Boynton Ph.D.	Founder, Chief Scientific Officer, Secretary & Director	375k	N/A	1945
Dr. Marnix L. Bosch M.B.A., Ph.D.	Chief Technical Officer	453.6k	74k	1959
Mr. Leslie J. Goldman	Senior VP & General Counsel	725k	N/A	1945
Mr. David Innes	Vice President of Investor Relations	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Corporate Governance

Northwest Biotherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.